CohBar’s First Mitochondria Based Therapy Shows Promise In NASH

New Modality In Hard-To-Crack Field

 
• By Andrew McConaghie
  
Liver disease
Problems with safety and efficacy in various candidates mean that the US FDA has still not approved the first NASH therapy.

More from Alimentary/Metabolic

More from Therapy Areas